Rademann

Prof. Dr. Rademann leads the working group in Pharmaceutical and Medicinal Chemistry at the Department of Pharmacy, Freie Universität Berlin. His research focuses on fragment-based ligand discovery and dynamic ligation screening to develop high-affinity protein ligands for disease-related targets.

• Key areas: Protein-ligand recognition, cooperative fragment interactions, chemical probe development
• Targets: SARS protease, Shp2 phosphatase, STAT5 transcription factor, protein-protein interactions

The group contributes to ChemBioNet, a national collaboration network for chemical biology screening, and develops novel synthetic methodologies including C-acylations for peptide derivatives. Research projects are funded by the European Commission, Investitionsbank Berlin, and Collaborative Research Centers (SFB 765, CRC 1349).

Former team members include numerous PhD researchers and postdoctoral associates. The group's innovations in fragment ligation assays and bioactive molecule synthesis bridge chemical synthesis, structural biology, and pharmacological validation across cancer, Alzheimer's, and infectious disease models.